Corporate Members
The Pennsylvania Society of Oncology and Hematology expresses its gratitude to our corporate members. Contirbutions from the following companies help us in fulfilling our mission.
To learn more about becoming a Corporate Member, please click here.
To learn more about becoming a Corporate Member, please click here.
10k Members
Amgen
About Us:
At Amgen Oncology, our mission to serve patients drives all that we do. That's why we're relentlessly focused on accelerating the delivery of medicines that have the potential to empower all angles of care and transform lives of people with cancer. For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.
Representatives
Grace DeMartini
Social Media
At Amgen Oncology, our mission to serve patients drives all that we do. That's why we're relentlessly focused on accelerating the delivery of medicines that have the potential to empower all angles of care and transform lives of people with cancer. For the last four decades, we have been dedicated to discovering the firsts that matter in oncology and to finding ways to reduce the burden of cancer. Building on our heritage, Amgen continues to advance the largest pipeline in the Company's history, moving with great speed to advance those innovations for the patients who need them.
Representatives
Grace DeMartini
Social Media
AbbVie
About Us:
AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio comprises of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Oncology Research & Treatment
AbbVie advances cancer research and treatment to elevate the standard of care for blood cancer patients, and in the future other cancers like solid tumors.
Representatives
Judith Aronson
Kathy Wagner
Jim Lajeunesse
Jay Raczkowski
Steve Quarin
Social Media
AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for patients living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities including Antibody Drug Conjugates (ADCs), Immuno-Oncology, bi-specific/multi-specific antibody and CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines. Today, our expansive oncology portfolio comprises of approved and investigational treatments for a wide range of blood and solid tumors. We are evaluating more than 20 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.
Oncology Research & Treatment
AbbVie advances cancer research and treatment to elevate the standard of care for blood cancer patients, and in the future other cancers like solid tumors.
Representatives
Judith Aronson
Kathy Wagner
Jim Lajeunesse
Jay Raczkowski
Steve Quarin
Social Media
AstraZeneca
About Us:
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. AstraZeneca Oncology has a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
Representative Contact
Jessica Klouser
Tamara Lenzi
Social Media
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide. AstraZeneca Oncology has a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.
Representative Contact
Jessica Klouser
Tamara Lenzi
Social Media
Bayer
About Us:
At Bayer, we are committed to improving patients' lives. Continuing a 150-year legacy leading the world in life sciences innovation, Bayer reaffirms our commitment to improving patients’ lives every day. We will continue working to develop therapies and deliver the first-in-class support and education programs that help today’s patients — and tomorrow’s.
Representative Contacts
Juan Gonsalves
Sarah Blasser
Maryanne Vechercofski
Social Media
At Bayer, we are committed to improving patients' lives. Continuing a 150-year legacy leading the world in life sciences innovation, Bayer reaffirms our commitment to improving patients’ lives every day. We will continue working to develop therapies and deliver the first-in-class support and education programs that help today’s patients — and tomorrow’s.
Representative Contacts
Juan Gonsalves
Sarah Blasser
Maryanne Vechercofski
Social Media
BeOne Medicines
About Us
(formerly BeiGene - Press Release)
We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.
Representative
Brent Coleman
(formerly BeiGene - Press Release)
We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.
Representative
Brent Coleman
Boehringer Ingelheim
About us: Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow.
Representatives
Sara Lompardo
Phone
Additional Contacts: Jonathan Liess, Kathaleen Lampenfeld
Representatives
Sara Lompardo
Phone
Additional Contacts: Jonathan Liess, Kathaleen Lampenfeld
Bristol Myers Squibb
About us: Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Representative
Rich Boyle
Associate Director – US State Societies and Congresses
US Hematology & Cell Therapy Portfolio Marketing and Channel Strategy
Mobile
Representative
Rich Boyle
Associate Director – US State Societies and Congresses
US Hematology & Cell Therapy Portfolio Marketing and Channel Strategy
Mobile
Daiichi Sankyo
Exelixis
About Us
Our story is one of dedication to patients and to scientific excellence. Over the course of the past three decades, we’ve evolved into a multi-platform cancer company. Today, we are innovating with both small molecules and biotherapeutics to build a diversified portfolio of cancer treatments that give patients hope for the future.
Representative:
Bob Zeigler - Senior Oncology Account Manager
Mobile
Our story is one of dedication to patients and to scientific excellence. Over the course of the past three decades, we’ve evolved into a multi-platform cancer company. Today, we are innovating with both small molecules and biotherapeutics to build a diversified portfolio of cancer treatments that give patients hope for the future.
Representative:
Bob Zeigler - Senior Oncology Account Manager
Mobile
Gilead
GSK
About Us
At GSK Oncology our ambition is to help increase overall quality of life, maximize survival and change the course of disease.
Representatives
Robin Beerhalter, Oncology Account Manager/Hematology, Philadelphia S.
Maria Calderaro, Oncology Account Manager, Philadelphia N.
Karl Bonsell, Oncology Account Manager/Hematology, Central PA
Gretchen Spitzer, Oncology Account Manager, Central PA
At GSK Oncology our ambition is to help increase overall quality of life, maximize survival and change the course of disease.
Representatives
Robin Beerhalter, Oncology Account Manager/Hematology, Philadelphia S.
Maria Calderaro, Oncology Account Manager, Philadelphia N.
Karl Bonsell, Oncology Account Manager/Hematology, Central PA
Gretchen Spitzer, Oncology Account Manager, Central PA
Incyte
About Incyte
Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. Since 2002 Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. Incyte’s unique expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing portfolio of medicines across two franchises: Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in the U.S., Europe and Japan. For more information, click here and follow @Incyte.
Contacts
Wendy McGarry, Executive Oncology Hematology Specialist, MPN
Mitch Mench, Senior Oncology Hematology Specialist, LST
Phil Holloway, GVHD Key Account Manager - Phila
Shawn Britton, Director, Regional Key Account Management - Mid-Atlantic
Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. Since 2002 Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders. Incyte’s unique expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing portfolio of medicines across two franchises: Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in the U.S., Europe and Japan. For more information, click here and follow @Incyte.
Contacts
Wendy McGarry, Executive Oncology Hematology Specialist, MPN
Mitch Mench, Senior Oncology Hematology Specialist, LST
Phil Holloway, GVHD Key Account Manager - Phila
Shawn Britton, Director, Regional Key Account Management - Mid-Atlantic
Jazz Pharma
About Us
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. We are a leader in sleep disorders and epilepsy; further developing in movement disorders and PTSD; and focused on hematologic malignancies and solid tumors. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules, biologics, innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. We are a leader in sleep disorders and epilepsy; further developing in movement disorders and PTSD; and focused on hematologic malignancies and solid tumors. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules, biologics, innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. Please visit www.jazzpharmaceuticals.com for more information.
Janssen
About Us:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Social Media
@JNJInnovMed
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.
Social Media
@JNJInnovMed
Merck
About Us:
Our focus on cancer research and treatments: We work with urgency to pursue breakthrough science to not only prolong lives, but protect them, too. Because people with cancer deserve more — more ways to treat their cancer, more quality in their lives and more time. We’re committed to advancing cancer research with one of the largest development programs in the industry across more than 30 tumor types.
Representative Contact
Mark Montello
Social Media Links
Our focus on cancer research and treatments: We work with urgency to pursue breakthrough science to not only prolong lives, but protect them, too. Because people with cancer deserve more — more ways to treat their cancer, more quality in their lives and more time. We’re committed to advancing cancer research with one of the largest development programs in the industry across more than 30 tumor types.
Representative Contact
Mark Montello
Social Media Links
Pfizer Oncology
About Us:
With over 2 decades of scientific innovation across oncology, Pfizer continues to drive the next wave of cancer breakthroughs. Approximately 40% of all our research and development investment is directed toward oncology.
We're dedicated to developing therapies in 5 key cancer types, including breast, genitourinary, hematologic, thoracic, and gastrointestinal cancers. This work spans 3 core modalities to attack cancer from multiple angles: small molecules, antibody-drug conjugates (ADCs), and immuno-oncology biologics, including bispecific antibodies.
Representatives:
Geraldine Olson, CPC
Oncology Field Reimbursement Director
Work
Stephanie Grunwell
Oncology Key Account Director
Cell
With over 2 decades of scientific innovation across oncology, Pfizer continues to drive the next wave of cancer breakthroughs. Approximately 40% of all our research and development investment is directed toward oncology.
We're dedicated to developing therapies in 5 key cancer types, including breast, genitourinary, hematologic, thoracic, and gastrointestinal cancers. This work spans 3 core modalities to attack cancer from multiple angles: small molecules, antibody-drug conjugates (ADCs), and immuno-oncology biologics, including bispecific antibodies.
Representatives:
Geraldine Olson, CPC
Oncology Field Reimbursement Director
Work
Stephanie Grunwell
Oncology Key Account Director
Cell
PharmaEssentia
About Us: PharmaEssentia Corporation (TWSE: 6446), headquartered in Taipei, Taiwan, with U.S. subsidiaries in Burlington and Bedford, MA, is a rapidly growing and fully integrated biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, the company aims to deliver effective new biologics for diseases in the areas of hematology and oncology, with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives
and renowned scientists from U.S. biotechnology and pharmaceutical companies, the company has expanded its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung.
For more information, visit our website or find us on LinkedIn and X.
Representative Contact
Carmine Lenzi
Social Media
and renowned scientists from U.S. biotechnology and pharmaceutical companies, the company has expanded its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung.
For more information, visit our website or find us on LinkedIn and X.
Representative Contact
Carmine Lenzi
Social Media
Regeneron
About Us:
Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.
Representative Contacts
Melissa Taylor – Sr. Reimbursement Business Manager
John Honus – Oncology Account Specialist
Alex Forero – Oncology Account Specialist
Benity Sewell – Regional Director
Ashley Liwoski – Oncology Account Specialist
Amy Brown – Oncology Account Specialist
Social Media Links
Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.
Representative Contacts
Melissa Taylor – Sr. Reimbursement Business Manager
John Honus – Oncology Account Specialist
Alex Forero – Oncology Account Specialist
Benity Sewell – Regional Director
Ashley Liwoski – Oncology Account Specialist
Amy Brown – Oncology Account Specialist
Social Media Links
5k Members
AVEO Oncology
About Us
AVEO Pharmaceuticals, Inc., an LG Chem company, (AVEO) is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet need, including ficlatuzumab in HPV-negative refractory head and neck squamous cell carcinoma and rilogrotug (also known as AV-380) in cancer cachexia. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name.
Representatives
Michael Mcdonald
Oncology Account Manager
Phone
Kristine Dunbar
Regional Director
Phone
Social Media
AVEO Pharmaceuticals, Inc., an LG Chem company, (AVEO) is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO and its strategic partners continue to develop FOTIVDA in other novel targeted combinations in RCC. The company also has investigational programs in other areas of high unmet need, including ficlatuzumab in HPV-negative refractory head and neck squamous cell carcinoma and rilogrotug (also known as AV-380) in cancer cachexia. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name.
Representatives
Michael Mcdonald
Oncology Account Manager
Phone
Kristine Dunbar
Regional Director
Phone
Social Media
Eli Lilly and Company
About Lilly:
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn.
For questions on the corporate boilerplate, please contact [email protected].
Representatives
Kevin Coyne
Sr. Executive Account Manager, Regional Oncology
Lilly Value and Access
Mobile Phone
Jennifer Mercado
Executive Business Director, Philadelphia Oncology District
Office Phone | Mobile Phone
Social Media
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom or follow us on Facebook, Instagram, Twitter and LinkedIn.
For questions on the corporate boilerplate, please contact [email protected].
Representatives
Kevin Coyne
Sr. Executive Account Manager, Regional Oncology
Lilly Value and Access
Mobile Phone
Jennifer Mercado
Executive Business Director, Philadelphia Oncology District
Office Phone | Mobile Phone
Social Media
EMD Serono
Menarini Stemline
About Us:
Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Our dedicated team of scientists, specialists, researchers, and developers are committed to providing transformational oncology treatments to those who need it, with the ultimate goal of improving the lives of those impacted by cancer.
Representative
Angela Csaszar, Director, Oncology Access
Social Media
Stemline Therapeutics, Inc. (“Stemline”) a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Our dedicated team of scientists, specialists, researchers, and developers are committed to providing transformational oncology treatments to those who need it, with the ultimate goal of improving the lives of those impacted by cancer.
Representative
Angela Csaszar, Director, Oncology Access
Social Media
Natera
Representatives
Tricia Barrick
Gabriel Iacono
Tricia Barrick
Gabriel Iacono
Novartis
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Representatives
Dolly Sandhu-Papa
Stacey Griffith
Bethanne Schmid
Marybeth Lythgoe
Patient Support Resources
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Representatives
Dolly Sandhu-Papa
Stacey Griffith
Bethanne Schmid
Marybeth Lythgoe
Patient Support Resources
